A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock

Infection and Immunity

Volumn 81, Issue 1, 2013, Pages 90-98

  Piccioni, M ^a   Monari, C ^a   Kenno, S ^a   Pericolini, E ^a   Gabrielli, E ^a   Pietrella, D ^a   Perito, S ^a   Bistoni, F ^a   Kozel, T R ^b   Vecchiarelli, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOXYLOMANNAN; I KAPPA B ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ESCHERICHIA COLI; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; CRYPTOCOCCUS NEOFORMANS; I-KAPPA B KINASE; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; POLYSACCHARIDES; PROTO-ONCOGENE PROTEINS C-AKT; SERUM; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871854308     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00553-12     Document Type: Article

References (59)

1. Mitchell TG, Perfect JR. 1995. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
2. Cherniak R. 1988. Soluble polysaccharides of Cryptococcus neoformans. Curr. Top. Med. Mycol. 2:40-54.
3. Goldman DL, Lee SC, Casadevall A. 1995. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448-3453.
4. Lee SC, Casadevall A, Dickson DW. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol. 148:1267-1274.
5. Cherniak R, Sundstrom JB. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
6. Vecchiarelli A. 2007. Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit. Rev. Immunol. 27:547-557
7. Yauch LE, Lam JS, Levitz SM. 2006. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2:e120. doi:10.1371/journal.ppat.0020120.
8. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. 2009. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68:133-216.
9. Bennett JE, Hasenclever HF, Tynes BS. 1964. Detection of cryptococcal polysaccharide in serum and spinal fluid: value in diagnosis and prognosis. Trans. Assoc. Am. Physicians 77:145-150.
10. Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, Kozel TR. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect. Immun. 63:2919-2923.
11. Monari C, Bistoni F, Casadevall A, Pericolini E, Pietrella D, Kozel TR, Vecchiarelli A. 2005. Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J. Infect. Dis. 191:127-137.
12. Monari C, Paganelli F, Bistoni F, Kozel TR, Vecchiarelli A. 2008. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell. Microbiol. 10:2129-2137.
13. McInnes IB, Schett G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7:429-442.
14. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227-242.
15. Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell. Signal. 13:85-94.
16. Lu YC, Yeh WC, Ohashi PS. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42:145-151.
17. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. 2003. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 33:97-605.
18. Stoll LL, Denning GM, Weintraub NL. 2006. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr. Pharm. Des. 12:4229-4245.
19. Johnson DA, Sowell CG, Johnson CL, Livesay MT, Keegan DS, Rhodes MJ, Ulrich JT, Ward JR, Cantrell JL, Brookshire VG. 1999. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 9:2273-2278.
20. Christ WJ, Asano O, Robidoux ALC, Perez M, Wang Y, Dubuc GR, Gavin WE, Hawkins LD, McGuinness PD, Mullarkey MA, Lewis MD, Kishi Y, Kawata T, Bristol JR, Rose JR, Rossignol DP, Kobayashi S, Hishinuma L, Kimura A, Asakawa N, Katayama K, Yamatsu I. 1995. E5531, a pure endotoxin antagonist of high potency. Science 268:80-83.
21. Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. 2010. Salvage effect of E5564, Toll-like receptor 4 antagonist on D-galactosamine and lipopolysaccharide induced acute liver failure in rats. J. Gastroenterol. Hepatol. 25:1009-1012.
22. Wittebole X, Castanares-Zapatero D, Laterre PF. 2010. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010: 568396. doi:10.1155/2010/568396.
23. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. 2011. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin. Drug Metab. Toxicol. 7:479-494.
24. Monari C, Kozel TR, Paganelli F, Pericolini E, Perito S, Bistoni F, Casadevall A, Vecchiarelli A. 2006. Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. J. Immunol. 177: 6842-6851.
25. Council of Europe. 2010. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. Directive 2010/63/EU. Council of Europe, Strasbourg, Brussels, Belgium.
26. Cherniak R, Reiss E, Slodki ME, Plattner RD, Blumer SO. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol. Immunol. 17:1025-1032.
27. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neofor-mans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
28. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Møller K. 2008. Human endotoxemia as a model of systemic inflammation. Curr. Med. Chem. 15:1697-1705.
29. Zhang WJ, Wei H, Hagen T, Frei B. 2007. Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 104:4077-4082.
30. Lawrence T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1:a001651. doi:10.1101/ cshperspect.a001651.
31. Lepper PM, Held TK, Schneider EM, Bölke E, Gerlach H, Trautmann M. 2002. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 28:824-833.
32. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. 2008. Experimental models of sepsis and their clinical relevance. Shock 30(Suppl 1):53-59.
33. Tissi L, Puliti M, Bistoni F, Mosci P, Kozel TR, Vecchiarelli A. 2004. Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis. Infect. Immun. 72:6367-6372.
34. Monari C, Bevilacqua S, Piccioni M, Pericolini E, Perito S, Calvitti M, Bistoni F, Kozel TR, Vecchiarelli A. 2009. A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production. J. Immunol. 183:191-200
35. Dauphinee SM, Karsan A. 2006. Lipopolysaccharide signaling in endothelial cells. Lab. Invest. 86:9-22.
36. Ward SG, Finan P. 2003. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3:426-434.
37. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD. 2007. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404:15-21.
38. Carver DJ, Aman MJ, Ravichandran KS. 2000. SHIP inhibits Akt activation in B cells through regulation of Akt membrane localization. Blood 96:1449-1456.
39. Yauch LE, Mansour MK, Shoham S, Rottman JB, Levitz SM. 2004. Involvement of CD14, Toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect. Immun. 72:5373-5382.
40. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166:4620-4626.
41. Cavaillon JM, Annane D. 2006. Compartmentalization of the inflamma-tory response in sepsis and SIRS. J. Endotoxin Res. 12:151-170
42. Martin H, Olander B, Norman M. 2001. Reactive hyperemia and inter-leukin 6, interleukin 8, and tumor necrosis factor-alpha in the diagnosis of early-onset neonatal sepsis. Pediatrics 108:E61.
43. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. 2008. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum. Reprod. 23:2017-2023.
44. Choi YH, Park HY. 2012. Anti-inflammatory effects of spermidine in lipopolysaccharide-stimulated BV2 microglial cells. J. Biomed. Sci. 19:31.
45. Zeytun A, Chaudhary A, Pardington P, Cary R, Gupta G. 2010. Induction of cytokines and chemokines by Toll-like receptor signaling: strategies for control of inflammation. Crit. Rev. Immunol. 30:53-67.
46. Hansson GK, Robertson AK, Soderberg-Naucler C. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1:297-329.
47. O'Shea JJ, Ma A, Lipsky P. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37-45.
48. Williams LM, Lali F, Willetts K, Balague C, Godessart N, Brennan F, Feldmann M, Foxwell BM. 2008. Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol. Immunol. 45:2446-2454.
49. Lin WW, Karin M. 2007. A cytokine mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117:117511-117583.
50. Kumar H, Kawai T, Akira S. 2009. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388:621-625.
51. Turjanski AG, Vaque JP, Gutkind JS. 2007. MAP kinases and the control of nuclear events. Oncogene 26:3240-3253.
52. Yang ZZ, Tschopp O, Baudry A, Dümmler B, Hynx D, Hemmings BA. 2004. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 32:350-354.
53. Dummler B, Hemmings BA. 2007. Physiological roles of PKB/Akt iso-forms in development and disease. Biochem. Soc. Trans. 35:231-235.
54. Song G, Ouyang G, Bao S. 2005. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9:59-71.
55. Liao Y, Hung MC. 2010. Physiological regulation of Akt activity and stability. Am. J. Transl. Res. 2:19-42.
56. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, Vogel SN. 2009. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J. Leukoc. Biol. 85:966-977.
57. Kane LP, Shapiro VS, Stokoe D, Weiss A. 1999. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9:601-604.
58. Wang ZL, Wu XH, Song LF, Wang YS, Hu XH, Luo YF, Chen ZZ, Ke J, Peng XD, He CM, Zhang W, Chen LJ, Wei YK. 2009. Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice. Biochem. Biophys. Res. Commun. 386:569-574.
59. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko F, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ. 2005. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front. Biosci. 10:975-987.